HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Supraglottic lesion — Clinical Guidelines

Overview

Supraglottic lesions primarily encompass malignancies originating in the supraglottic region of the larynx, including areas such as the aryepiglottic folds, arytenoid cartilages, and the upper part of the arytenoid mucosa. These lesions are clinically significant due to their potential impact on airway patency, voice quality, and overall survival rates. They predominantly affect adults, with a higher incidence observed in smokers and those with chronic alcohol use. Accurate diagnosis and tailored management are crucial for optimizing patient outcomes and minimizing complications. Understanding the nuances of supraglottic lesions is essential for clinicians to provide effective treatment strategies and improve patient care in day-to-day practice 1 2 3 4 5.

Pathophysiology

The pathophysiology of supraglottic cancers typically involves genetic mutations and epigenetic alterations that disrupt normal cellular regulation, leading to uncontrolled proliferation. Commonly implicated molecular pathways include alterations in the p53 tumor suppressor gene and activation of oncogenes such as RAS and MYC. These genetic changes often result in dysregulated cell cycle progression and enhanced angiogenesis, facilitating tumor growth and invasion. The hyoepiglottic ligament (HL), a critical anatomical barrier, plays a pivotal role in limiting the spread of cancer from the supraglottis to deeper structures like the preepiglottic and paraglottic spaces. However, when breached, cancer can extend cephalad into regions such as the suprahyoid epiglottis and aryepiglottic folds, complicating treatment and prognosis 4.

Epidemiology

Supraglottic cancers represent a significant portion of laryngeal malignancies, with an estimated incidence varying by geographic region but generally affecting males more frequently than females, often with a peak incidence in the sixth to seventh decades of life. Smoking and alcohol consumption are well-established risk factors, contributing to a higher prevalence in populations with these habits. Over time, there has been a noted decline in incidence rates in some regions due to increased awareness and reduced smoking rates, though disparities persist globally. The variability in tumor shape and size, as highlighted by observer variability studies, underscores the need for precise imaging and contouring techniques in managing these cases 1 2 5.

Clinical Presentation

Patients with supraglottic lesions often present with a range of symptoms including hoarseness, dysphagia, sore throat, and chronic cough. Atypical presentations may include referred otalgia or neck masses. Red-flag features include acute airway obstruction, significant weight loss, and persistent unexplained fever, which necessitate urgent evaluation. Hoarseness persisting beyond two weeks should prompt thorough investigation to rule out malignancy 2 3.

Diagnosis

The diagnostic approach for supraglottic lesions involves a combination of clinical evaluation, imaging, and histopathological confirmation. Key steps include:

Endoscopy: Direct visualization of the larynx to identify lesions.

Fiberoptic Laryngoscopy: Provides detailed images for assessment.

Contrast-Enhanced CT/MRI: Essential for delineating tumor extent and involvement of surrounding structures.

Fine Needle Aspiration (FNA) or Biopsy: Definitive diagnosis through histopathological examination.

Specific Criteria and Tests:

Endoscopic Findings: Presence of ulceration, mass, or irregular mucosal changes.

Imaging Criteria: Tumor size, involvement of hyoepiglottic ligament, and extension into paraglottic or preepiglottic spaces.

Histopathology: Confirmation of malignancy through biopsy analysis.

Differential Diagnosis:

- Reactive Lesions: Inflammatory or reactive conditions can mimic malignancies; biopsy differentiates. - Benign Tumors: Such as papillomas or polyps; histopathological examination clarifies. - Metastatic Disease: Consider in patients with known malignancies; imaging and cytology help distinguish 1 4 5.

Management

Primary Treatment Approaches

#### Surgical Management

Transoral Laser Microsurgery (TLM): Suitable for early-stage tumors; shorter setup time compared to robotic surgery.

- Indications: T1-T2 lesions. - Complications: Intraoperative bleeding (52% in TLM vs 26% in TORS) 2.

Transoral Robotic Surgery (TORS): Offers precision and dexterity for complex cases.

- Indications: Larger or more complex tumors. - Setup Time: Longer compared to TLM.

Coblation-Assisted Transoral Supraglottic Laryngectomy (TSL): Effective for properly selected cases.

- Indications: T1-T3N2M0 supraglottic cancers. - Outcome: En bloc resection with negative margins, minimal postoperative complications 3.

#### Radiation Therapy

Intensity-Modulated Radiation Therapy (IMRT): Precise targeting to minimize damage to surrounding tissues.

- Dose: Typically 60-70 Gy in fractions. - Fractionation: 30-35 fractions over 6-7 weeks. - Contouring Challenges: High variability in tumor contouring among experts 1.

#### Chemoradiation

Combination of Chemotherapy and Radiation: Used for advanced stages.

- Chemotherapy Agents: Platinum-based regimens (e.g., cisplatin). - Radiation Dose: Similar to IMRT, adjusted based on tumor stage and patient tolerance.

Second-Line and Refractory Management

Recurrent or Persistent Disease: Consider salvage surgery or re-irradiation.

- Re-irradiation: Requires careful patient selection due to cumulative toxicity risks. - Systemic Therapy: Targeted therapies or immunotherapy for advanced cases, based on molecular profiling 5.

Contraindications:

Severe comorbidities precluding surgery or radiation.

Poor performance status affecting treatment tolerance.

Complications

Acute Complications

Intraoperative Bleeding: Particularly noted in TLM.

Airway Obstruction: Immediate postoperative risk requiring vigilant monitoring.

Postoperative Infections: Risk mitigated by prophylactic antibiotics.

Long-Term Complications

Voice Alteration: Common post-surgery; speech therapy may be necessary.

Tracheoesophageal Fistula: Rare but serious complication requiring surgical intervention.

Recurrent Disease: Regular follow-up imaging and endoscopy crucial for early detection 2 3.

Prognosis & Follow-up

The prognosis for supraglottic cancers varies based on stage at diagnosis and treatment efficacy. Early-stage lesions generally have better outcomes with curative intent treatments. Prognostic indicators include:

Tumor Stage: Earlier stages (T1-T2) correlate with better survival rates.

Lymph Node Involvement: N0 status is favorable.

Histological Grade: Well-differentiated tumors fare better.

Recommended Follow-Up:

Initial Postoperative Period: Frequent (weekly to monthly) clinical assessments and imaging.

Long-Term Monitoring: Every 3-6 months for the first 2 years, then annually thereafter.

Endoscopic Surveillance: Essential for early detection of recurrence 5.

Special Populations

Pediatrics

Supraglottic lesions are rare in pediatric populations, but when present, they often require multidisciplinary pediatric ENT and oncology care tailored to developmental considerations.

Elderly Patients

Elderly patients may face increased surgical risks and comorbidities, necessitating careful risk stratification and possibly less aggressive treatment approaches.

Comorbidities

Patients with significant comorbidities (e.g., cardiovascular disease, respiratory compromise) require individualized treatment plans balancing efficacy with safety profiles.

Specific Ethnic Risk Groups

Certain ethnic groups with higher smoking rates or occupational exposures (e.g., certain agricultural workers) may exhibit higher incidence rates, warranting targeted screening programs 2 5.

Key Recommendations

Accurate Tumor Contouring: Utilize experienced multidisciplinary teams for precise CT-based tumor contouring to minimize treatment margins and improve outcomes (Evidence: Moderate 1).

Multidisciplinary Approach: Combine expertise from ENT surgeons, radiation oncologists, and pathologists for comprehensive patient management (Evidence: Strong 2).

Surgical Techniques: Choose TLM for early-stage lesions and TORS for more complex cases, considering setup time and expertise availability (Evidence: Moderate 2).

Radiation Therapy Precision: Employ IMRT to target tumors accurately while sparing surrounding tissues (Evidence: Strong 1).

Regular Follow-Up: Implement rigorous follow-up protocols including endoscopic surveillance every 3-6 months for the first two years post-treatment (Evidence: Moderate 5).

Consider Chemoradiation for Advanced Stages: Use combination therapy for advanced tumors to enhance local control and survival (Evidence: Moderate 5).

Monitor for Recurrent Disease: Early detection through regular imaging and clinical assessments is crucial for managing recurrences (Evidence: Moderate 3).

Address Comorbidities: Tailor treatment plans considering patient comorbidities to optimize outcomes and minimize complications (Evidence: Expert opinion 2).

Voice Rehabilitation: Provide speech therapy post-surgery to mitigate voice alterations (Evidence: Expert opinion 3).

Targeted Therapy for Recurrent Cases: Consider molecular profiling for targeted therapies in recurrent or refractory disease (Evidence: Weak 5).

References

1 Cooper JS, Mukherji SK, Toledano AY, Beldon C, Schmalfuss IM, Amdur R et al.. An evaluation of the variability of tumor-shape definition derived by experienced observers from CT images of supraglottic carcinomas (ACRIN protocol 6658). International journal of radiation oncology, biology, physics 2007. link 2 Loubieres C, Hans S, Lechien JR, Ansarin M, Atallah S, Barbut J et al.. Expert perspectives for transoral robotic versus laser surgery for supraglottic carcinomas. European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery 2025. link 3 Zhao J, Li J. Coblation-assisted transoral supraglottic laryngectomy. Ear, nose, & throat journal 2025. link 4 Zeitels SM, Kirchner JA. Hyoepiglottic ligament in supraglottic cancer. The Annals of otology, rhinology, and laryngology 1995. link 5 Robbins KT, Gray L, Michaels L. Statistical correlations among supraglottic cancers. The Annals of otology, rhinology, and laryngology 1988. link

Supraglottic lesion